Traws Pharma Defers Planned Phase 2a Influenza Study Of Tivoxavir Marboxil After Negative UK MHRA Review; Cash Runway Extends To Q1 2027; Advancing Alternative Influenza Antiviral Candidates

Traws Pharma, Inc.

Traws Pharma, Inc.

TRAW

0.00

-SEC Filing

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.